Principal Investigator
David Baidal
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20220563
Clinical Trial Summary
A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents with Recent-Onset Type 1 Diabetes Mellitus
Phase
Phase III
Funding Agency/Sponsor
Industry
Disease
Other
Contact Information
Study Contact
Burlett Masters
Phone Number
+1 (305) 2435354
Email
bmasters2@miami.edu